Abstract

Objective: To analyze whether the use of tamoxifen is a feasible option in repeated unresponsive thin endometrium (<6 mm) with standard treatment options. Methods: Three consecutive women undergoing Frozen Embryo Transfer (FET) who, after standard endometrial preparation, still showed thin endometrium (<6 mm). They were all given with tamoxifen treatment. Results: Successful endometrial expansion to at least 7.7 mm after tamoxifen treatment in three patients previously with thin endometrium in abandoned IVF cycles, natural cycles and extended estrogen treatment cycles with aspirin. All the three patients performed embryo-transfer, and they all conceived. One singleton stopped growing on gestational week 8. Two deliveries produced three healthy children. Conclusion: In patients of recurrent thin endometrium, regardless of whether abandoned IVF cycles, natural cycles or extended estrogen treatment cycles with aspirin, tamoxifen treatment may be a successful alternative approach.

Highlights

  • Adequate growth of the endometrium is an important factor for successful implantation

  • Endometrial thickness

  • We report three cases with recurrent thin endometrium

Read more

Summary

Introduction

Adequate growth of the endometrium is an important factor for successful implantation. Some authors have reported that there is a steady and gradual increase in pregnancy rates as endometrial thickness increases [1]. When endometrial thickness is

Methods
Results
Discussion
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.